Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
90.14
+1.21 (1.36%)
At close: Dec 20, 2024, 4:00 PM
90.00
-0.14 (-0.16%)
After-hours: Dec 20, 2024, 4:55 PM EST
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 120.79, with a low estimate of 76 and a high estimate of 168. The average target predicts an increase of 34.00% from the current stock price of 90.14.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BPMC stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 6 | 6 | 6 | 6 | 7 |
Buy | 5 | 6 | 6 | 6 | 7 | 7 |
Hold | 4 | 4 | 4 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Total | 15 | 17 | 17 | 18 | 19 | 20 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +38.67% | Dec 9, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +38.67% | Nov 18, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +49.77% | Nov 15, 2024 |
Needham | Needham | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +49.77% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
518.93M
from 249.38M
Increased by 108.09%
Revenue Next Year
723.08M
from 518.93M
Increased by 39.34%
EPS This Year
-1.00
from -8.37
EPS Next Year
-0.97
from -1.00
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 548.8M | 811.7M | 1.2B | |||
Avg | 518.9M | 723.1M | 959.8M | |||
Low | 493.4M | 560.7M | 744.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 120.1% | 56.4% | 63.5% | |||
Avg | 108.1% | 39.3% | 32.7% | |||
Low | 97.8% | 8.0% | 3.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.82 | 3.06 | 6.04 | ||
Avg | -1.00 | -0.97 | 1.74 | ||
Low | -1.23 | -2.78 | -1.22 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.